

Client: ACCESS MEDICAL L			Patient: TEST, PATIE				
5151 CORPORATE W JUPITER, FL 33458	AY		Phone: () - Address 1: Address 2:	DOB. 01/01/1980	Age:44 Sex: M Fasting: N		
Phys: SARA, ALAN	(561) 745-	-1233	City:	State: Zi	p: Page:1		
Acc# 005261160	Coll. Date: 11/20/24		Recv. Date: 11/20/24	Print Date: 11/21/2	24		
Chart# First reported on:	Coll. Time: 00:00 AM 11/20/24 15:36		Recv. Time:07:30 AM Final report date:	Print Time: 11:58 11/20/24			
Report Status: FINAL							
Test Name			Results	Reference Range	Units		
COMPLETE BLOOD C	OUNT			-			
WHITE BLOOD CELL			10.0	3.9 - 11.4	K/ul		
RED BLOOD CELL			4.50	4.20 - 6.00	M/ul		
HEMOGLOBIN			15	13.2 - 18.0	g/dl		
HEMATOCRIT			45	42.0 - 56.0	%		
MCV			95	83 - 102	fl		
МСН			30.0	26.0 - 34.0	pg		
MCHC			32.0	29.5 - 35.5	g/dl		
RDW			13.0	11.0 - 15.5	%		
PLATELET COUNT			250	140 - 400	k/ul		
MPV			10.0	7.5 - 11.6	fl		
AUTOMATED DIFFER	ENTIAL				<i></i>		
Lymphocyte %			35	15.0 - 49.0	%		
Monocyte %			10	2.0 - 13.0	%		
MANUAL DIFFERENT	IAL						
Segmented Neutrophil %)		50	Not Estab.	%		
Lymphocyte %			35	Not Estab.	%		
Monocyte %			10	Not Estab.	%		
Eosinophil %			4	Not Estab.	%		
Basophil %			1	Not Estab.	%		
GENERAL CHEMISTR	RY						
GLUCOSE			85	65 - 100	mg/dl		
BUN			10	6 - 20	mg/dl		
CREATININE, SERUM			1.0	0.7 - 1.3	mg/dl		
SODIUM			140	136 - 145	mmol/L		
POTASSIUM			5.0	3.5 - 5.1	mmol/L		
CHLORIDE			107	100 - 110	mmol/L		
CO2			20	20 - 31	mmol/L		
CALCIUM			9.0	8.3 - 10.6	mg/dl		
TOTAL PROTEIN			6.9	5.7 - 8.2	g/dl		
ALBUMIN			4.0	3.2 - 4.8	g/dl		
GLOBULIN			2.9	2.1 - 3.6	g/dl		
BILIRUBIN, TOTAL			1.1	0.3 - 1.2	mg/dl		
	(Continued on N	Vext Pa		J.J 1.4			
	(Continued on N	vext Pag	ge)				



	NEDICAL LABS-						
Client: ACCESS MEDICAL LA	ABS, 0	1	Patient: TEST, PATIE	NT			
5151 CORPORATE WA		-	Phone: () -	DOB. 01/01/1980	Age:44 Sex: M		
JUPITER, FL 33458	11		Address 1:	DOD: 01/01/1/00	Fasting: N		
JUITIER, I'L 33438			Address 2:		Tasting. Iv		
	(5(1) 745	1000		St. (D 2		
Phys: SARA, ALAN	(561) 745	-1233	City:	State: Zi	p: Page:2		
Acc# 005261160	Coll. Date: 11/20/24		Recv. Date: 11/20/24	Print Date: 11/21/	24		
Chart#	Coll. Time: 00:00 AM		Recv. Time:07:30 AM	Print Time: 11:58	27		
First reported on:	11/20/24 15:36		Final report date:	11/20/24			
Report Status: FINAL							
Test Name			Results	Reference Range	Units		
GENERAL CHEMISTR	Y (Continued)				-		
ALKALINE PHOSPHAT	· · · · · · · · · · · · · · · · · · ·		45	45 - 115	U/L		
	ASE						
ALT			45	0 - 48	U/L		
AST			40 H	0 - 38	U/L		
Albumin/Globulin Ratio			1.4	0.8 - 2.0			
BUN/CREAT RATIO			N/A	7.3 - 21.7			
GFR, estimated			86		ml/min		
	If African	-Ameri	.can, result is: >60				
	Calculation of estimated GFR is based on the MDRD Study prediction equation						
		Five :	Stages of Chronic Kidr	-			
	Stage		*GFR Level*	*Descripti			
	Stage 1	90	ml/min or more	Healthy Kidneys o			
				damage with norma			
Stage 2			to 89 ml/min	Kidney damage and mild decrease in GFR			
Stage 3			30 to 59 ml/minModerate decrease in GFR15 to 29 ml/minSevere decrease in GFR				
	Stage 4			Severe decrease i			
	Stage 5	< 1	15 ml/min	Kidney failure, o	r on dialysis		
	NC						
	SN				0/		
HEMOGLOBIN A1C			5.0	< 5.7	%		
			Diagnagig	+ + + II	bA1c Level***		
			Diagnosis	ааан 1			
			Normal Prediabetes		< 5.7 % 5.7 - 6.4 %		
			Diabetes		5.7 - 6.4 %		
	Having prediabete	a ia :	a Risk Factor for gett				
	prediabetes range(5.7-6.4), the higher the HbAlc,the greater the risk of diabetes. HbAlc target for diabetics depend on their history and health.						
		5	L.	1			
IRON/ANEMIA EVALU							
IRON			20 L	65 - 175	ug/dl		
VITAMIN B12			500	211 - 911	pg/ml		
FOLATE, SERUM			21	5.38 - 24.0	ng/ml		
CORONARY RISK							
TRIGLYCERIDES	_		100	<150	mg/dl		
CHOLESTEROL, TOTA			150	<200	mg/dl		
	(Continued on I	Next Pag	ge)				



	MEDICAL LABS-					
Client: ACCESS MEDICAL LA		l	Patient: TEST, PATIE	NT		
5151 CORPORATE WA	AY		Phone: () -	DOB. 01/01/1980	Age:44 Sex: M	
JUPITER, FL 33458			Address 1:		Fasting: N	
			Address 2:			
Phys: SARA, ALAN	(561) 745	-1233	City:	State: Z	ip: Page:3	
Acc# 005261160	Coll. Date: 11/20/24		Recv. Date: 11/20/24	Print Date: 11/21	/24	
Chart#	Coll. Time: 00:00 AM		Recv. Time:07:30 AM	Print Time: 11:58		
First reported on:	11/20/24 15:36		Final report date:	11/20/24		
Report Status: FINAL						
Test Name			Results	Reference Range	Units	
CORONARY RISK (Co	ntinued)				-	
HDL CHOLESTEROL			50	>40	mg/dl	
LDL CHOLESTEROL, ca	alc		82	<100	mg/dl	
					0	
CHOL/HDL RATIO			3.0	<5.0		
The higher the Ratio, the higher CHD risk.						
CRP, Cardio			1.0	<3	mg/L	
Risk of Cardiovasular Disease						
Low Risk OF Cardiovasular Disease**						
	Medium	Risk	CRE	91.0-3.0 mg/I		
	High R	isk		CRP > 3.0 mg/I		
Vitamin D,25-OH,Total			31	30 - 100	ng/ml	
	Notes: Therapy is based	on th	e measurement of Total	Vitamin D (25-OF	I).	
			It Vitamin D deficiency			
	Vitamin D insufficiency is recognized as 21 - 29 ng/ml.					
		el fo	or Vitamin D (25-OH)is	recommended to be	e 30 - 100	
	ng/ml.					
	Vitamin D > 150 n	g/ml	is considered potentia	lly toxic.		
THYROID TESTING						
T3, FREE			3.2	2.3 - 4.2	pg/ml	
T4, FREE			25 H	0.89 - 1.76	ng/dl	
TSH			1.025	0.550 - 4.780	uIU/ml	
ENDOCRINE EVALUA	TION					
PROGESTERONE			1.0	0.28 - 1.22	ng/mL	
ESTRADIOL, LC/MS			20	0.28 - 1.22 <29.0	ng/mL pg/mL	
DHEA-SULFATE			20 30 L			
	AL LC/MS		30 L 45 L	34.5 - 568.9	ug/dl	
TESTOSTERONE, TOTAL LC/MS SEX HORMONE BIND GLOBULIN			45 L 15	264.0 - 916.0 15 - 95	ng/dL nmol/L	
IGF-1	JEUDULIN		235 H			
101-1	(Continued on N	Vext Pa		113 - 172	ng/mL	
		ient I d	5~)			



Client: ACCESS MEDICAL LA 5151 CORPORATE WA JUPITER, FL 33458 Phys: SARA, ALAN		1233	Patient: TEST, PATIEN Phone: () - Address 1: Address 2: City:	NT DOB. 01/01/1980 State: Zij	Age:44 Sex: M Fasting: N p: Page:4	
Chart#	Coll. Date: 11/20/24 Coll. Time: 00:00 AM 11/20/24 15:36		Recv. Date: 11/20/24 Recv. Time:07:30 AM Final report date:	Print Date: 11/21/2 Print Time: 11:58 11/20/24	24	
Test Name			Results	Reference Range	Units	
ENDOCRINE EVALUAT	ION (Continued)			Kelerence Kange	00	
	Access Medical Lak supplier for IGF-1	L Immu of IC	ories uses Siemens Hea moassay Testing Syste FF-1 assay using WHO 1	m. Siemens Introdu	uced a	
CORTISOL			20		ug/dl	
	Normal	L indi	viduals			
Morning am 7-9: 5.2 - 22.5 ug/dL Afternoon pm 3-5 : 3.4 - 16.8 ug/dL						
Testosterone, Free LC/MS Lab Developed Testing			1.2 L ******	4.1 - 23.0	ng/dl	
Serum Pregnenolone, DHT, Estrone, Estriol, RT3, CO-Q10, Total Testosterone LC/MS, Androstenedione LC/MS, Progesterone LC/MS, and Estradiol LC/MS were developed and their performance characteristics determined by Access Medical Laboratories. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA and qualified to perform high-complexity testing. These tests are used for clinical purposes. It should not be regarded as investigational or for research.						
AUTO IMMUNE. Antinuclear Antibodies, M ANA Screen ANA INTERPRETATION			NEGATIVE ******	NEGATIVE		
	CLINICAL SUSPICION	1	ANTI NUCLEAR AU	TO ANTIBODIES INVO	DLVED	
	SLE		ANTI-dsDNA, ANTI-Sm, ANTI-CHROMATIN, ANTI			
	(Continued on N	lext Pag		-SSA (One of more	POPICIAE)	



Client: ACCESS MEDICAL I 5151 CORPORATE W JUPITER, FL 33458 Phys: SARA, ALAN		1233	Patient: TEST, PATIE Phone: () - Address 1: Address 2: City:	DOB. 01/01/1980	Age:44 Sex: M Fasting: N ip: Page:5
Acc# 005261160 Chart# First reported on: Report Status: FINAL	Coll. Date: 11/20/24 Coll. Time: 00:00 AM 11/20/24 15:36		Recv. Date: 11/20/24 Recv. Time:07:30 AM Final report date:	Print Date: 11/21/ Print Time: 11:58 11/20/24	24
Test Name			Results	Reference Range	Units
AUTO IMMUNE. (Con	tinued) SCLERODERMA SJOGREN'S SYNDROME POLYMYOSITIS OR DERMATOMYOSITIS DRUG-INDUCED LUPUS MIXED CONNECTIVE TISSUE DISEASE (MCT	3	ANTI-SCL-70, ANTI-CE ANTI-SS-A, ANTI-SS-E ANTI-JO-1 ANTI-CHROMATIN (no f ANTI-SM/RNP, ANTI-RN (at least RNP positiv	3 (both positive) Surther testing) MP, ANTI-CHROMATIN	
COMMENTS:		E]	ND OF REPORT		

